biotech · Recurrent Pericarditis · Acute Myocarditis · CRDL
Cardiol Therapeutics
Cardiol Therapeutics is a biotech organization headquartered in Toronto, CA. It trades on NYSE under ticker CRDL. Primary therapeutic focus areas include Recurrent Pericarditis, Acute Myocarditis, Spontaneous Coronary Ar
2265 Upper Middle Rd E, Suite 602, Greater Toronto Area, Ontario L6H 0G5, CA HQ
2017 Founded
27 Employees
Public company Type
CRDL · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2265 Upper Middle Rd E, Suite 602, Greater Toronto Area, Ontario L6H 0G5, CA
- Founded
- 2017
- Employees
- 27
- Programs
- 11
- Drugs
- 31
- Patents
- 15
CARDIOL 100-03
Phase 3 · small molecule · COVID-19
CARDIOL 100-03 for COVID-19 is a Phase 3 program (small_molecule) at Cardiol Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code CARDIOL 100-03
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Cardiol Therapeutics
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- COVID-19
- Status
- terminated
- Trials
- 1